Proteomics of p53 in Diagnostics and Therapy of Acute Myeloid Leukemia

Nina Ånensen¹ - nina.anensen@med.uib.no
Ingvild Haaland¹ - ingvild.haaland@student.uib.no
Clive D'Santos²
Werner Van Belle³ - werner@yellowcouch.org, werner.van.belle@gmail.com
Bjørn Tore Gjertsen^1,4* - bjorn.gjertsen@med.uib.no

1- Institute of Medicine Hematology Section University of Bergen Haukeland University Hospital; Bergen; Norway
2- Proteomic Unit (Probe) University of Bergen ; Bergen; Norway
3- Bioinformatics Group Norut IT; Research Park; 9294 Tromsø; Norway
4- Department of Internal Medicine Hematology Section Haukeland University Hospital; Bergen; Norway
* Corresponding author

Abstract :  The anti-oncogene TP53 is frequently mutated in human cancer, but in hematological malignancies this is a rare feature. In acute myeloid leukemia (AML) more than 90% of the patients comprise wild type TP53 in their cancer cells, but if TP53 is mutated or deleted the disease is often found to be chemoresistant. In this review we define proteomics of the oncogene product p53 as the study of proteins in the p53 regulating signaling networks, as well as the protein study of members of the p53 family itself. Various messenger RNA splice forms as well as a multitude of posttranslational modifications give a high number of protein isoforms in the p53 family. Some of the proteomic techniques allow detection of various isoforms, such as two-dimensional gel electrophoresis in combination with tandem mass spectrometry (MS/MS) and this methodology may therefore increasingly be used as a diagnostic tool in human disease. We introduce the p53 protein as an illustration of the complexity of post-translational modifications that may affect one highly connected protein and discuss the possible impact in AML diagnostics if the p53 profile is reflecting cell stress and status of signal transduction systems of the malignancy

Keywords:  proteomics, P53, 2D correlation gel analysis
Reference:  Nina Ånensen, Ingvild Haaland, Clive D'Santos, Werner Van Belle, Bjørn Tore Gjertsen; Proteomics of p53 in Diagnostics and Therapy of Acute Myeloid Leukemia; Current Pharmaceutical Biotechnology; Bentham Science Publishers Ltd.; volume 7; nr 3; July 2006
Files: Gjertsen-MS.pdf